Intensity of anticoagulation in the treatment of thrombosis in the antiphospholipid syndrome: A meta-analysis

Revista Brasileira de Reumatologia

Volumn 55, Issue 2, 2015, Pages 159-166

  da Silva, Felipe Freire ^a   de Carvalho, Jozélio Freire ^b  

^a ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

^b Rheumatology Division Centro Médico Do Hospital Aliança   (Brazil)

Author keywords

Antiphospholipid syndrome; Hemorrhage; Thrombosis; Warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLEEDING; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT OUTCOME; CHEMICALLY INDUCED; COMPLICATION; HEMORRHAGE;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; HEMORRHAGE; HUMANS; RISK ASSESSMENT; THROMBOSIS; WARFARIN;

EID: 84929677005     PISSN: 04825004     EISSN: 18094570     Source Type: Journal    
DOI: 10.1016/j.rbr.2014.08.016     Document Type: Short Survey

References (36)

1. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. Guidelines on the investigation and management ofantiphospholipid syndrome. Br J Haematol. 2012;157:47-58.
2. Sangle NA, Smock KJ. Antiphospholipid Antibody Syndrome. Arch Pathol Lab Med. 2011;135:1092-6.
3. Santamaria JR, Badziak D, Barros MF, Mandelli FL, Cavalin LC,Sato MS. Síndrome antifosfolípide. An Bras Dermatol. 2005;80:225-39.
4. Hanly JG. Antiphospholipid syndrome: an overview. CMAJ. 2003;168:1675-82.
5. Espinosa G, Cervera R. Antiphospholipid syndrome. ArthritisRes Ther. 2008;10:230.
6. Hughes GRV. Antiphospholipid syndrome (Hughessyndrome): 10 clinical topics. Lupus. 2010;19:343-6.
7. Petri M. Management of thrombosis in antiphospholipidantibody syndrome. Rheum Dis Clin North America. 2001;27:633-42.
8. Lourenço DM, Lopes LH, Vignal CV, Morelli VM. Avaliaçãoclínica e laboratorial de pacientes em uso de anticoagulantesorais. Arq Bras Cardiol. 1997;68:353-6.
9. Crowther M, Crowther MA. Intensity of warfarin coagulationin the antiphospholipid syndrome. Curr Rheumatol Rep. 2010;12:64-9.
10. Ruiz-Irastorza G, Hunt BJ, Khamashita MA. A systematicreview of secundary thromboprophylaxis in patients with theantiphospholipid antibodies. Arthritis Rheum. 2007;57:1487-95.
11. Del Papa N, Vaso N. Management of antiphospholipidsyndrome. Ther Adv Musculoskel Dis. 2010;2:221-7.
12. Tuthill JI, Khamashta MA. Management of antiphospholipidsyndrome. J Autoimmun. 2009;33:92-8.
13. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ,Hughes GR. The management of thrombosis in theantiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993-7.
14. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinicalcourse after the first thrombotic event in 70 patients. AnnIntern Med. 1992;117:303-8.
15. Ruiz-Irastorza G, Khamashta MA, Hunt BJ, Escudero A,Cuadrado MJ, Hughes GR. Bleeding and recurrent thrombosisin definite antiphospholipid syndrome: analysis of a seriesof 66 patients treated with oral anticoagulation to a targetinternational normalized ratio of 3.5. Arch Intern Med. 2002;162:1164-9.
16. Derksen RHWM, Groot Ph G, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venousthrombosis should receive long term anticoagulanttreatment. Ann Rheum Dis. 1993;52:689-92.
17. Krnic-Barrie S, O'Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients withantiphospholipid syndrome. Analysis of factors influencingrecurrent thrombosis. Arch Intern Med. 1997;157:2101-8.
18. Muñoz-Rodriguez FJ, Font J, Cervera R, Reverter JC, Tàssies D,Espinosa G, et al. Clinical study and follow-up of 100 patientswith the antiphosphlipid syndrome. Semin Arthritis Rheum. 1999;29:182-90.
19. Wittkowsky AK, Downing J, Blackburn J, Nutescu E. Warfarin-related outcomes in patients with antiphospholipidantibody syndrome managed in an anticoagulation clinic. Thromb Haemost. 2006;96:137-41.
20. Lim W, Crowther MA, Eikelboom JW. Management ofantiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295:1050-7.
21. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: theseventh ACCP conference on antithrombotic andthrombolytic therapy. Chest. 2004;126:287S-310S.
22. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW,Piette JC, et al. International consensus statementon preliminary classification criteria for definiteantiphospholipid syndrome: report of an internationalworkshop. Arthritis Rheum. 1999;42:1309-11.
23. Miyakis S, Lockshin MD, Atsumi T, Branch DC, Brey RL,Cervera R, et al. International consensus statement on anupdate of the classification criteria for definiteantiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
24. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ,Gavaghan DJ, et al. Assessing the quality of reports ofrandomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
25. Downs SH, Black N. The feasibility of creating a checklistfor the assessment of the methodological quality both ofrandomized and non-randomized studies of health careinterventions. J Epidemiol Community Health. 1998;52:377-84.
26. Review Manager (RevMan) [Computer program]. Version 5.2.Copenhagen: The Nordic Cochrane Centre, The CochraneCollaboration, 2012.
27. Mantel N, Haenszel MW. Statistical aspects of thee analysis ofdata from retrospective studies of disease. J Nat Cancer Inst. 1959;22:719-48.
28. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing dataand undertaking meta-analyses. In: Higgins JPT, Green S,editores. Cochrane Handbook for Systematic Reviews ofInterventions. Version 5.0.1 [updated September 2008]. TheCochrane Collaboration, 2008. Disponível em:.
29. Mannocci A. The Mantel-Haenszel procedure. 50 years of thestatistical method for confounders control. Ital J PublicHealth. 2009;6:338-40.
30. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J,Douketis J, et al. A comparison of two intensities of warfarinfor the prevention of recurrent thrombosis in patients withthe antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133-8.
31. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F,Musial J, et al. A randomized clinical trial of high intensitywarfarin vs. conventional antithrombotic therapy for theprevention of recurrent thrombosis in patients with theantiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848-53.
32. Girón-González JA, Del Río EG, Rodríguez C,Rodríguez-Martorell J, Serrano A. Antiphospholipid syndromeand asymptomatic carriers of antiphospholipid antibody:prospective analysis of 404 individuals. J Rheumatol. 2004;31:1560-7.
33. Ames PRJ, Ciampa A, Margaglione M, Scenna G, Iannaccone L,Brancaccio V. Bleeding and re-thrombosis in primaryantiphospholipid syndrome on oral anticoagulation. ThrombHaemost. 2005;93:694-9.
34. Riera R, Abreu MM, Ciconelli RM. Revisões sistemáticase meta-análises na reumatologia. Rev Bras Reumatol. 2006;46:8-11.
35. Atallah AN. Revisões sistemáticas da literaturae meta-análise. Diagn Tratamento. 1997;2:12-5.
36. Cervera R, Asherson RA. Antiphospholipid Syndrome. In:Shoenfeld Y, Cervera R, Gershwin GE, editors. DiagnosticCriteria in Autoimmune Diseases. Totowa, NJ: Humana Press;2008. p. 9-14.